These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

784 related articles for article (PubMed ID: 9682348)

  • 1. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
    Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
    Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin.
    Yang C; Collins WE; Xiao L; Saekhou AM; Reed RC; Nelson CO; Hunter RL; Jue DL; Fang S; Wohlhueter RM; Udhayakumar V; Lal AA
    Vaccine; 1997 Mar; 15(4):377-86. PubMed ID: 9141208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.
    Teixeira LH; Tararam CA; Lasaro MO; Camacho AG; Ersching J; Leal MT; Herrera S; Bruna-Romero O; Soares IS; Nussenzweig RS; Ertl HC; Nussenzweig V; Rodrigues MM
    Infect Immun; 2014 Feb; 82(2):793-807. PubMed ID: 24478093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of H-2 restriction of the Plasmodium falciparum (NANP) sequence as multiple antigen peptide.
    Pessi A; Valmori D; Migliorini P; Tougne C; Bianchi E; Lambert PH; Corradin G; Del Giudice G
    Eur J Immunol; 1991 Sep; 21(9):2273-6. PubMed ID: 1889465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge.
    de Camargo TM; de Freitas EO; Gimenez AM; Lima LC; de Almeida Caramico K; Françoso KS; Bruna-Romero O; Andolina C; Nosten F; Rénia L; Ertl HCJ; Nussenzweig RS; Nussenzweig V; Rodrigues MM; Reyes-Sandoval A; Soares IS
    Sci Rep; 2018 Jan; 8(1):1118. PubMed ID: 29348479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin.
    Leal MT; Camacho AG; Teixeira LH; Bargieri DY; Soares IS; Tararam CA; Rodrigues MM
    Clin Vaccine Immunol; 2013 Sep; 20(9):1418-25. PubMed ID: 23863502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
    Kingston NJ; Kurtovic L; Walsh R; Joe C; Lovrecz G; Locarnini S; Beeson JG; Netter HJ
    Vaccine; 2019 Mar; 37(12):1674-1684. PubMed ID: 30773400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multiple antigen peptide from the repetitive sequence of the Plasmodium malariae circumsporozoite protein induces a specific antibody response in mice of various H-2 haplotypes.
    Del Giudice G; Tougne C; Louis JA; Lambert PH; Bianchi E; Bonelli F; Chiappinelli L; Pessi A
    Eur J Immunol; 1990 Jul; 20(7):1619-22. PubMed ID: 2201549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.
    Przysiecki C; Lucas B; Mitchell R; Carapau D; Wen Z; Xu H; Wang XM; Nahas D; Wu C; Hepler R; Ottinger E; Ter Meulen J; Kaslow D; Shiver J; Nardin E
    Front Cell Infect Microbiol; 2012; 2():146. PubMed ID: 23226683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice.
    Shabani SH; Zakeri S; Mortazavi Y; Mehrizi AA
    Med Microbiol Immunol; 2019 Dec; 208(6):731-745. PubMed ID: 31025102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of Multifunctional Broadly Reactive T Cell Responses by a Plasmodium vivax Circumsporozoite Protein Recombinant Chimera.
    Cabrera-Mora M; Fonseca JA; Singh B; Oliveira-Ferreira J; Lima-Junior Jda C; Calvo-Calle JM; Moreno A
    Infect Immun; 2015 Sep; 83(9):3749-61. PubMed ID: 26169267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fine epitope specificity of antibodies to region II of the Plasmodium vivax circumsporozoite protein correlates with ability to bind recombinant protein and sporozoites.
    Bilsborough J; Baumgart K; Bathurst I; Barr P; Good MF
    Acta Trop; 1997 May; 65(2):59-80. PubMed ID: 9164601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate.
    Milich DR; Hughes J; Jones J; Sällberg M; Phillips TR
    Vaccine; 2001 Dec; 20(5-6):771-88. PubMed ID: 11738741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
    Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S
    PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a Genetically Modified Chimeric
    Miyazaki Y; Marin-Mogollon C; Imai T; Mendes AM; van der Laak R; Sturm A; Geurten FJA; Miyazaki S; Chevalley-Maurel S; Ramesar J; Kolli SK; Kroeze H; van Schuijlenburg R; Salman AM; Wilder BK; Reyes-Sandoval A; Dechering KJ; Prudêncio M; Janse CJ; Khan SM; Franke-Fayard B
    Front Cell Infect Microbiol; 2020; 10():591046. PubMed ID: 33392104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint.
    Porter MD; Nicki J; Pool CD; DeBot M; Illam RM; Brando C; Bozick B; De La Vega P; Angra D; Spaccapelo R; Crisanti A; Murphy JR; Bennett JW; Schwenk RJ; Ockenhouse CF; Dutta S
    Clin Vaccine Immunol; 2013 Jun; 20(6):803-10. PubMed ID: 23536694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic peptide immunogens eliciting antibodies to Plasmodium falciparum sporozoite and merozoite surface antigens in H-2b and H-2k mice.
    Rzepczyk CM; Csurhes PA; Lord R; Matile H
    J Immunol; 1990 Oct; 145(8):2691-6. PubMed ID: 2212657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.
    McCoy ME; Golden HE; Doll TA; Yang Y; Kaba SA; Zou X; Gerbasi VR; Burkhard P; Lanar DE
    Malar J; 2013 Apr; 12():136. PubMed ID: 23607541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum.
    Clement F; Dewar V; Van Braeckel E; Desombere I; Dewerchin M; Swysen C; Demoitié MA; Jongert E; Cohen J; Leroux-Roels G; Cambron P
    Malar J; 2012 Nov; 11():384. PubMed ID: 23173602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.